Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 44

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 44
---
 significant changes in fair value during the changes in significant assumptions which influence the fair value measurement for financial liabilities associated with contingent consideration arrangements.

|                                             |     | JPY (millions)                            
 Six-month Period Ended September 30, 2025 |        |
|:--------------------------------------------|:----|:------------------------------------------|-------:|
| As of the beginning of the period           |     |                                           |  4,362 |
| Changes in the fair value during the period |     |                                           |    253 |
| Foreign currency translation differences    |     |                                           | -1,469 |
| As of the end of the period                 |     |                                           |  3,145 |

(6) Financial instruments not measured at fair value

The carrying amount and fair value of financial instruments that are not measured at fair value in the condensed interim consolidated statements of financial position are as follows. Fair value information is not provided for financial instruments, if the carrying amount is a reasonable estimate of fair value due to the relatively short period of maturity of these instruments.

|                 |     | JPY (millions)           
 As of September 30, 2025 |           |     |            |           |
|:----------------|:----|:-------------------------|----------:|:----|:-----------|----------:|
|                 |     | Carrying                 
 amount                   |           |     | Fair value |           |
| Bonds           |     |                          | 4,405,252 |     |            | 4,110,758 |
| Long-term loans |     |                          |   240,003 |     |            |   235,362 |

Long-term financial liabilities are recognized at their carrying amount. The fair value of bonds is measured at quotes whose significant inputs to the valuation model used are based on observable market data. The fair value of loans is measured at the present value of future cash flows discounted using the applicable market rate on the loans in consideration of the credit risk by each group classified in a specified period. The fair value of bonds and long-term loans are classified as Level 2 in the fair value hierarchy.

<div align='center'>- 39 -</div>

Translation for reference purpose only

#### 12. Subsequent Events
In October 2025, Takeda entered into a license and collaboration agreement with Innovent Biologics, Inc. ("Innovent") for the development, manufacturing and commercialization of two late-stage investigational medicines for solid tumors, IBI363